| Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126, 2019 | 466 | 2019 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 282 | 2022 |
| A reference viral database (RVDB) to enhance bioinformatics analysis of high-throughput sequencing for novel virus detection N Goodacre, A Aljanahi, S Nandakumar, M Mikailov, AS Khan MSphere 3 (2), 10.1128/mspheredirect. 00069-18, 2018 | 137 | 2018 |
| Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer KH Stopsack, S Nandakumar, AG Wibmer, S Haywood, ES Weg, ... Clinical Cancer Research 26 (13), 3230-3238, 2020 | 126 | 2020 |
| A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2) YZ Mazzu, J Armenia, G Chakraborty, Y Yoshikawa, SAA Coggins, ... Clinical Cancer Research 25 (14), 4480-4492, 2019 | 120 | 2019 |
| Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression Clinical Cancer Research, 2020 | 94* | 2020 |
| Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics B Nguyen, JM Mota, S Nandakumar, KH Stopsack, E Weg, D Rathkopf, ... European urology 78 (5), 671-679, 2020 | 84 | 2020 |
| Whole-genome sequence of the Spodoptera frugiperda Sf9 insect cell line S Nandakumar, H Ma, AS Khan Genome announcements 5 (34), 10.1128/genomea. 00829-17, 2017 | 41 | 2017 |
| Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors KH Stopsack, S Nandakumar, K Arora, B Nguyen, SE Vasselman, B Nweji, ... Clinical Cancer Research 28 (2), 318-326, 2022 | 31 | 2022 |
| Specific mutations in APC, but not alterations in DNA damage response, associate with outcomes of patients with metastatic colorectal cancer S Mondaca, H Walch, S Nandakumar, WK Chatila, N Schultz, R Yaeger Gastroenterology 159 (5), 1975-1978. e4, 2020 | 28 | 2020 |
| Genetic ancestry correlates with somatic differences in a real-world clinical cancer sequencing cohort K Arora, TN Tran, Y Kemel, M Mehine, YL Liu, S Nandakumar, SA Smith, ... Cancer discovery 12 (11), 2552-2565, 2022 | 27 | 2022 |
| BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling L Shaashua, A Ben-Shmuel, M Pevsner-Fischer, G Friedman, ... Nature communications 13 (1), 6513, 2022 | 25 | 2022 |
| Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer YZ Mazzu, J Armenia, S Nandakumar, G Chakraborty, Y Yoshikawa, ... Molecular oncology 14 (8), 1881-1897, 2020 | 24 | 2020 |
| Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer YZ Mazzu, Y Yoshikawa, S Nandakumar, G Chakraborty, J Armenia, ... Molecular Oncology 13 (9), 1944-1958, 2019 | 19 | 2019 |
| Quantifying the expanding landscape of clinical actionability for patients with cancer SP Suehnholz, MH Nissan, H Zhang, R Kundra, S Nandakumar, C Lu, ... Cancer Discovery 14 (1), 49-65, 2024 | 17 | 2024 |
| Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors G Chakraborty, NK Patail, R Hirani, S Nandakumar, YZ Mazzu, ... Clinical Cancer Research 27 (6), 1792-1806, 2021 | 16 | 2021 |
| The Spodoptera frugiperda Sf9 cell line is a heterogeneous population of rhabdovirus-infected and virus-negative cells: Isolation and characterization of cell clones containing … H Ma, S Nandakumar, EH Bae, PJ Chin, AS Khan Virology 536, 125-133, 2019 | 16 | 2019 |
| The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer G Chakraborty, S Nandakumar, R Hirani, B Nguyen, KH Stopsack, ... Clinical Cancer Research 28 (16), 3603-3617, 2022 | 10 | 2022 |
| Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer H Truong, K Breen, S Nandakumar, DD Sjoberg, Y Kemel, N Mehta, ... European Urology 83 (1), 29-38, 2023 | 9 | 2023 |
| Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity YZ Mazzu, YR Liao, S Nandakumar, M Sjöström, LE Jehane, R Ghale, ... Molecular Oncology 16 (13), 2451-2469, 2022 | 9 | 2022 |
Goutam ChakrabortyIcahn School of Medicine at Mount Sinai, New YorkVerified email at mountsinai.org
